Is a severely damaged Biogen looking to shed its ties to a controversial development partner?
After taking it on the chin throughout Thursday and Friday for its questionable strategy of sticking with the amyloid beta theory on Alzheimer’s — topped by the news that its partner Eisai had picked one of the worst moments possible to launch a new Phase III trial of their other Alzheimer’s drug BAN2401 — Biogen ended the week with a statement that stopped far short of a ringing endorsement of the move by their collaborators.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.